...
首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung.
【24h】

Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung.

机译:非典型腺瘤性增生和肺支气管肺泡癌中表皮生长因子受体基因的突变。

获取原文
获取原文并翻译 | 示例
           

摘要

A hypothesis of multistep carcinogenesis of lung adenocarcinoma from atypical adenomatous hyperplasia (AAH) to invasive adenocarcinoma through bronchioloalveolar carcinoma (BAC) has been proposed. However, the genetic alterations that play a role during these processes are not yet clear. Recently, somatic mutations of the epidermal growth factor receptor (EGFR) gene were found in lung adenocarcinoma. We examined the status of EGFR mutations in AAH and BAC to elucidate the role they play during multistage of lung adenocarcinoma. We found somatic EGFR mutations in 3% (1/35) of AAH, 10.8% (4/37) of BAC and 41.9% (13/31) of invasive adenocarcinoma. Sixteen of 18 EGFR mutations were found in exon 19 and two were in exon 21. Among the 16 EGFR mutations in exon 19, 13 were deletions of 15bp and one was an insertion/duplication of 18bp. Mutations of the K-ras gene were detected in 26.7% (8/30) of AAH, 16.7% (5/30) of BAC and 10% (3/30) of invasive adenocarcinoma. None of the tumors with EGFR mutations had K-ras mutation simultaneously. Patients who had invasive adenocarcinoma with EGFR mutations were younger than those without mutations (60.6 versus 67.4 years, p=0.03). These results suggest that tumors with EGFR mutations may progress more rapidly and develop into invasive cancer faster than those without mutations. Alternatively it is also possible that some invasive adenocarcinomas with EGFR mutations may not follow the AAH-adenocarcinoma sequence. We analyzed 24 patients with multiple lung lesions and 13 patients had at least one lesion that had either an EGFR or K-ras mutation. In all cases each lesion had a different mutation status. This finding suggests that the genetic alterations responsible for the development of lung adenocarcinoma occur randomly even under exposure to the same carcinogen.
机译:有人提出了从非典型腺瘤性增生(AAH)到支气管肺泡癌(BAC)的浸润性腺癌的肺腺癌多步骤癌变的假说。但是,尚不清楚在这些过程中起作用的遗传改变。最近,在肺腺癌中发现了表皮生长因子受体(EGFR)基因的体细胞突变。我们检查了AAH和BAC中EGFR突变的状态,以阐明它们在肺腺癌多阶段中的作用。我们在3%(1/35)的AAH,10.8%(4/37)的BAC和41.9%(13/31)的浸润性腺癌中发现了体细胞EGFR突变。在外显子19中发现18个EGFR突变中的16个,在外显子21中发现了2个。在外显子19中的16个EGFR突变中,有13个是15bp的缺失,一个是18bp的插入/重复。在AAH的26.7%(8/30),BAC的16.7%(5/30)和浸润性腺癌的10%(3/30)中检测到K-ras基因突变。 EGFR突变的肿瘤均未同时具有K-ras突变。具有EGFR突变的浸润性腺癌患者比没有突变的浸润性腺癌患者年轻(60.6岁对67.4岁,p = 0.03)。这些结果表明,具有EGFR突变的肿瘤可能比没有突变的肿瘤进展更快,并发展成浸润性癌症。或者,也有可能某些具有EGFR突变的浸润性腺癌可能不遵循AAH-腺癌序列。我们分析了24例多发肺部病变的患者,其中13例具有至少一个具有EGFR或K-ras突变的病变。在所有情况下,每个病变的突变状态都不同。这一发现表明,即使暴露于相同的致癌物下,导致肺腺癌发展的遗传改变也是随机发生的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号